C-type lectin domain family 1 member BGenealiases: 1810061I13Rik · CLEC2 · PRO1384 · QDED721
Q-omics provides the consensus-scored CLEC1B profile across patient tissues and cancer cell-line models. CLEC1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, CLEC1B is differentially expressed in 9, with the highest sampling consensus in LUAD. Additionally, CLEC1B RNA expression shows 14,314 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ESCA, LUAD, and UVM as cancer lineages where CLEC1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC1B survival associations across molecular data types. CLEC1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC1B RNA expression–survival associations across cancer types. High CLEC1B expression shows unfavorable associations in THYM and LGG, but favorable associations in ESCA, SKCM, LIHC and MESO. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ESCA as the clearest survival context for CLEC1B RNA expression.
This table summarizes CLEC1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CLEC1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC1B shows lower tumor expression in LUAD, LIHC, LUSC and CHOL and higher tumor expression in KIRC and HNSC. The LUAD box plot shows higher CLEC1B RNA expression in normal versus tumor tissue (log2 FC = −0.703, t-test p < 0.001).
This table shows molecular features associated with CLEC1B in patient tissues and cancer cell lines. In patient samples, CLEC1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
